CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 241.92 AUD -0.43% Market Closed
Market Cap: 117.1B AUD

Relative Value

The Relative Value of one CSL stock under the Base Case scenario is 262.65 AUD. Compared to the current market price of 241.92 AUD, CSL Ltd is Undervalued by 8%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CSL Relative Value
Base Case
262.65 AUD
Undervaluation 8%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
98
vs Industry
60
Median 3Y
6.5
Median 5Y
8.3
Industry
7.1
Forward
4.8
vs History
98
vs Industry
6
Median 3Y
37.9
Median 5Y
38.6
Industry
23
Forward
24
vs History
96
vs Industry
7
Median 3Y
33.5
Median 5Y
33.3
Industry
19.4
vs History
60
vs Industry
4
Median 3Y
54.2
Median 5Y
70.5
Industry
23.1
vs History
98
vs Industry
23
Median 3Y
5.5
Median 5Y
6.2
Industry
2.6
vs History
98
vs Industry
47
Median 3Y
7.2
Median 5Y
8.5
Industry
7.5
Forward
5.3
vs History
98
vs Industry
36
Median 3Y
14
Median 5Y
15.7
Industry
9.4
vs History
98
vs Industry
8
Median 3Y
22.7
Median 5Y
24.5
Industry
4.4
Forward
15.8
vs History
98
vs Industry
7
Median 3Y
28.1
Median 5Y
29
Industry
4.5
Forward
18.5
vs History
84
vs Industry
5
Median 3Y
35.8
Median 5Y
35.5
Industry
5.2
vs History
88
vs Industry
3
Median 3Y
80.5
Median 5Y
77.3
Industry
3.7
vs History
98
vs Industry
43
Median 3Y
3.1
Median 5Y
5.2
Industry
4.8

Multiples Across Competitors

CSL Competitors Multiples
CSL Ltd Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
CSL Ltd
ASX:CSL
117.1B AUD 5 27.7 17.1 21.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 789 962.7 -165 351.5 -200 789.5 -198 498.2
US
Abbvie Inc
NYSE:ABBV
334.6B USD 5.8 80.6 15.3 22.7
US
Amgen Inc
NASDAQ:AMGN
156.4B USD 4.6 26.4 14.2 23.4
US
Gilead Sciences Inc
NASDAQ:GILD
140.7B USD 4.9 23.6 10.2 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD 10.4 -116.8 24.8 26
US
Epizyme Inc
F:EPE
94.1B EUR 2 025 -516.7 -562.7 -547.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
55.3B USD 3.9 12.3 10.9 12.2
US
Seagen Inc
F:SGT
39.3B EUR 19.5 -59.8 -64.4 -58.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.6B USD 16.9 -146.8 -657.3 -329.4
NL
argenx SE
XBRU:ARGX
31.2B EUR 13.8 33.4 137 148.4
P/S Multiple
Revenue Growth P/S to Growth
AU
CSL Ltd
ASX:CSL
Average P/S: 3 162 915.7
5
7%
0.7
FR
Pharnext SCA
OTC:PNEXF
34 789 962.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.4
10%
1
US
E
Epizyme Inc
F:EPE
2 025
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
3.9
4%
1
US
S
Seagen Inc
F:SGT
19.5
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.9
29%
0.6
NL
argenx SE
XBRU:ARGX
13.8
39%
0.4
P/E Multiple
Earnings Growth PEG
AU
CSL Ltd
ASX:CSL
Average P/E: 34
27.7
16%
1.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 351.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.6
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.6
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -116.8 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.3
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -146.8 N/A N/A
NL
argenx SE
XBRU:ARGX
33.4
28%
1.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBITDA: 32.8
17.1
11%
1.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 789.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.8
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.9
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -657.3 N/A N/A
NL
argenx SE
XBRU:ARGX
137
727%
0.2
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBIT: 38.3
21.4
14%
1.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 498.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.4
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -547.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -329.4 N/A N/A
NL
argenx SE
XBRU:ARGX
148.4
N/A N/A